Recherche partagée · Trouver qui travaille sur votre propre sujet
Gut Microbiome and Checkpoint Inhibitor Response
Comment lire cette carte et vérifier ses sources ? Guide illustré
D'après 114 articles sur ce sujet publiés depuis 2021, retenus parmi les 371 résultats les plus pertinents de nos recherches sur OpenAlex. La pertinence n'a été vérifiée que pour les 120 articles les plus proches.
C'est un échantillon du domaine, pas un recensement : un sujet large compte bien plus d'articles qu'une carte n'en lit. Resserrez le sujet ou modifiez les recherches pour bien en cartographier une partie.
Les 4 recherches lancées sur OpenAlex · Une vue d'ensemble du domaine
- gut microbiome checkpoint inhibitor response cancer
- microbiome immunotherapy clinical biomarkers
- gut bacteria checkpoint blockade mechanisms
- fecal microbiota transplantation immunotherapy resistance
Le paysage
The first two approaches largely synthesize mechanisms and therapeutic possibilities, with the first centered on checkpoint inhibitors and the second extending to broader cancer immunity and immunotherapy. The third emphasizes clinical associations with response and toxicity, whereas the fourth focuses on extracting predictive signatures, including functional and gene-level features, with substantial attention to lung cancer. The fifth overlaps with mechanistic and intervention-oriented work while adding modeling and specific clinical questions, although its title-only evidence limits finer characterization.
Personnes
Classées selon les articles de la carte qu'elles signent, en comptant davantage ceux qu'elles signent en premier, en dernier ou comme auteur correspondant. L'ordre des auteurs dit qui a fait quoi dans beaucoup de domaines, pas qui dirige une équipe ; il n'est pas utilisé dans les listes d'auteurs alphabétiques, ni après les quinze premiers auteurs d'une grande collaboration.
-
Bertrand Routy
Microbiome Signatures for Response Prediction · 2Clinical Response and Toxicity Associations · 1
Ses articles sur le sujet
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
-
Karla A. Lee
Clinical Response and Toxicity Associations · 3Microbiome Modulation and Clinical Links · 1Microbiome Signatures for Response Prediction · 1
Ses articles sur le sujet
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
-
Rinse Karel Weersma
Clinical Response and Toxicity Associations · 2Microbiome Signatures for Response Prediction · 1
Ses articles sur le sujet
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer
-
Anqi Lin
Microbiota Across Cancer Immunotherapies · 1Checkpoint Response Mechanisms and Translation · 1
-
Daniel J. Spakowicz
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
-
Georgina Venetia Long
Microbiome Modulation and Clinical Links · 1Microbiota Across Cancer Immunotherapies · 1
-
Haitao Zhao
Clinical Response and Toxicity Associations · 2
-
Haoyan Chen
Clinical Response and Toxicity Associations · 1Microbiota Across Cancer Immunotherapies · 1
-
Jie Hong
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
-
Jun Qing Yu
Checkpoint Response Mechanisms and Translation · 1Microbiota Across Cancer Immunotherapies · 1
-
Khoudia Diop
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
Ses articles sur le sujet
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
-
Peng Luo
Microbiota Across Cancer Immunotherapies · 1Checkpoint Response Mechanisms and Translation · 1
-
Rebecca C. Simpson
Microbiome Modulation and Clinical Links · 1Microbiota Across Cancer Immunotherapies · 1
-
Saman Maleki Vareki
Microbiota Across Cancer Immunotherapies · 2
-
Wisam Nabeel Ibrahim
Checkpoint Response Mechanisms and Translation · 1Microbiota Across Cancer Immunotherapies · 1
-
Zhi Peng
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
-
Johannes R. Björk
Clinical Response and Toxicity Associations · 2Microbiome Signatures for Response Prediction · 1
Ses articles sur le sujet
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
-
Laura A. Bolte
Clinical Response and Toxicity Associations · 2Microbiome Signatures for Response Prediction · 1
Ses articles sur le sujet
- Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
-
Meriem Messaoudene
Microbiome Signatures for Response Prediction · 2Clinical Response and Toxicity Associations · 1
Ses articles sur le sujet
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
-
Amna Bibi
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
-
Arielle Elkrief
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
Ses articles sur le sujet
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
-
Francesca Romana Ponziani
Microbiome Signatures for Response Prediction · 1Clinical Response and Toxicity Associations · 1
-
Laurence Zitvogel
Microbiota Across Cancer Immunotherapies · 1Checkpoint Response Mechanisms and Translation · 1
-
Nyelia F. Williams
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
-
Xiang Li
Checkpoint Response Mechanisms and Translation · 1Microbiota Across Cancer Immunotherapies · 1
-
Zihan Han
Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
-
Xiaochen Yin
Clinical Response and Toxicity Associations · 1Microbiota Across Cancer Immunotherapies · 1Microbiome Signatures for Response Prediction · 1
Ses articles sur le sujet
-
Agnieszka Beata Malczewski
Checkpoint Response Mechanisms and Translation · 1
-
Aiping Zhou
Checkpoint Response Mechanisms and Translation · 1
Ses articles sur le sujet
-
Andrew A. Almonte
Checkpoint Response Mechanisms and Translation · 1
Ses articles sur le sujet
Institutions
Ce sont des affiliations de publication, pas des équipes de recherche identifiées. Un organisme national comme le CNRS peut regrouper plusieurs laboratoires indépendants.
Classées selon les articles qu'un de leurs auteurs signe en premier, en dernier ou comme auteur correspondant, puis selon leur part des articles : un article signé par quatre institutions compte un quart pour chacune, si bien qu'une grande collaboration ne fait pas paraître central chacun de ses membres.
-
Shanghai Jiao Tong University · CN
Microbiota Across Cancer Immunotherapies · 5Checkpoint Response Mechanisms and Translation · 2Clinical Response and Toxicity Associations · 1Microbiome Signatures for Response Prediction · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Jie Hong (2), Haoyan Chen (1), Jinkai Liu (1), Lijun Ning (1), Liliang Xia (1)
Articles correspondants avec cette affiliation
- Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response
- The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
- Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events
- Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
- The microbiome in cancer
-
University Medical Center Groningen · NL
Clinical Response and Toxicity Associations · 3Microbiome Signatures for Response Prediction · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Rinse Karel Weersma (2), Birgitta I. Hiddinga (1), Daoming Wang (1), Johannes R. Björk (1), Laura A. Bolte (1)
Articles correspondants avec cette affiliation
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Gut microbial structural variation associates with immune checkpoint inhibitor response
- Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
-
University of Groningen · NL
Clinical Response and Toxicity Associations · 3Microbiome Signatures for Response Prediction · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Rinse Karel Weersma (2), Birgitta I. Hiddinga (1), Daoming Wang (1), Johannes R. Björk (1), Laura A. Bolte (1)
Articles correspondants avec cette affiliation
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Gut microbial structural variation associates with immune checkpoint inhibitor response
- Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
-
The University of Texas MD Anderson Cancer Center · US
Clinical Response and Toxicity Associations · 2Checkpoint Response Mechanisms and Translation · 2Microbiota Across Cancer Immunotherapies · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Jianjun J. Zhang (1), Sai‐Ching J. Yeung (1), Stephanie S. Watowich (1), Yinghong Wang (1)
Articles correspondants avec cette affiliation
- Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
- Microbiome influencers of checkpoint blockade–associated toxicity
- The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
- 73 Fasting mediated gut microbiome modulation improves response to immune checkpoint therapy in Renal Cell Cancer
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
-
Huazhong University of Science and Technology · CN
Checkpoint Response Mechanisms and Translation · 2Clinical Response and Toxicity Associations · 1Microbiota Across Cancer Immunotherapies · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Hao Zhang (1), Tao Xie (1), Tian Xia (1), Xunhui Cai (1), Yuhang Xie (1)
Articles correspondants avec cette affiliation
- Gut Microbiome Control of Tumor Immune Checkpoint Inhibitor Response: Mechanistic Insights and Clinical Translation
- Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
- Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma
- The microbiome in cancer
-
Centre Hospitalier de l’Université de Montréal · CA
Clinical Response and Toxicity Associations · 2Microbiome Signatures for Response Prediction · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Bertrand Routy (2), Arielle Elkrief (1), Cecilia Hes (1), Khoudia Diop (1)
Articles correspondants avec cette affiliation
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
-
Renji Hospital · CN
Clinical Response and Toxicity Associations · 1Microbiota Across Cancer Immunotherapies · 1Microbiome Signatures for Response Prediction · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Jie Hong (2), Haoyan Chen (1), Jinkai Liu (1), Lijun Ning (1), Mengwei Zhang (1)
Articles correspondants avec cette affiliation
-
Chinese University of Hong Kong · HK
Microbiota Across Cancer Immunotherapies · 2Checkpoint Response Mechanisms and Translation · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Jun Qing Yu (2), Jun Yu (1), Mingxu Xie (1), Xing Kang (1)
-
Capital Medical University · CN
Checkpoint Response Mechanisms and Translation · 1Microbiota Across Cancer Immunotherapies · 1Clinical Response and Toxicity Associations · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Chengpei Zhu (1), Jianrong Su (1), Jie Zhang (1), Jingxin Ma (1), Qin Li (1)
Articles correspondants avec cette affiliation
-
Sichuan University · CN
Checkpoint Response Mechanisms and Translation · 2Microbiota Across Cancer Immunotherapies · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Hong Zhu (1), Jia Hu (1), Jie Xu (1), Li Yang (1), Ling‐Ling Zhu (1)
-
West China Hospital of Sichuan University · CN
Checkpoint Response Mechanisms and Translation · 2Microbiota Across Cancer Immunotherapies · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Hong Zhu (1), Jia Hu (1), Jie Xu (1), Li Yang (1), Ling‐Ling Zhu (1)
-
Qatar University · QA
Checkpoint Response Mechanisms and Translation · 1Microbiota Across Cancer Immunotherapies · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Wisam Nabeel Ibrahim (2), Sawsan Sudqi Said (1)
-
First Hospital of Lanzhou University · CN
Microbiota Across Cancer Immunotherapies · 1Checkpoint Response Mechanisms and Translation · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Jiexi Yan (1), Lei Jiang (1), Wei-Lin Jin (1), Yuehua Chen (1)
-
Chinese Academy of Medical Sciences & Peking Union Medical College · CN
Checkpoint Response Mechanisms and Translation · 2Microbiota Across Cancer Immunotherapies · 1Clinical Response and Toxicity Associations · 1
Signent ici en premier, en dernier ou comme auteur correspondant : Aiping Zhou (1), Chengpei Zhu (1), Haitao Zhao (1), Hanping Wang (1), Jinglong Huang (1)
Articles correspondants avec cette affiliation
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
- Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors
- The microbiome in cancer
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
-
Lawson Health Research Institute · CA
Microbiota Across Cancer Immunotherapies · 2
Signent ici en premier, en dernier ou comme auteur correspondant : Saman Maleki Vareki (2), Yeganeh Yousefi (1)
Approches
Les articles sont regroupés selon la similarité de leurs titres et résumés ; une IA nomme chaque groupe à partir de ses articles. Un article n'est que dans un groupe.
-
Checkpoint Response Mechanisms and Translation
These predominantly review papers synthesize how gut microbes, microbial metabolites, and immune interactions influence checkpoint inhibitor efficacy and toxicity, considering microbiome biomarkers and therapeutic modulation.
Personnes : Anqi Lin, Jun Qing Yu, Peng Luo, Wisam Nabeel Ibrahim, Laurence Zitvogel, Xiang Li
Institutions : Shanghai Jiao Tong University, The University of Texas MD Anderson Cancer Center, Huazhong University of Science and Technology, Sichuan University, West China Hospital of Sichuan University
Ses articles
- Gut Microbiome Control of Tumor Immune Checkpoint Inhibitor Response: Mechanistic Insights and Clinical Translation
- Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therapeutic implications-a narrative review
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review
- Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives
- Gut Microbiota and Immune Checkpoint Inhibitors: A Synergistic Approach in Hepatocellular Carcinoma Therapy
- Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
- The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists
- Microbiome dysbiosis and KRAS-driven tumorigenesis in pancreatic cancer: implications for immune checkpoint inhibitors efficacy
- Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
- Microbiota-centered interventions to boost immune checkpoint blockade therapies
- The gut microbiome and cancer response to immune checkpoint inhibitors
- Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
- Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
- Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors
- Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer
- Microbial Allies: How Gut Microbiota Influence the Effectiveness of Immune Checkpoint Inhibitors
- The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
- Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma
- Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)
- Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
- Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
- Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota
- Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity
- Microbiome influencers of checkpoint blockade–associated toxicity
- Modulating the gut microbiome to improve immune checkpoint inhibitor response to cancer: current therapies and emerging methods
- Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors
- Abstract C023: A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer
- Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
- Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
- The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application
- Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?
- Gut microbiome in modulating immune checkpoint inhibitors
- Gut Microbiota and Immunotherapy
- Gut Microbiota Potentiates the Effect of Immune Checkpoint Therapy against Cancers
- The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
-
Microbiota Across Cancer Immunotherapies
These reviews examine microbial effects on tumor development, systemic and antitumor immunity, and treatment outcomes across checkpoint blockade and other immunotherapies, including microbiota-directed interventions.
Personnes : Saman Maleki Vareki, Anqi Lin, Georgina Venetia Long, Haoyan Chen, Jun Qing Yu, Peng Luo
Institutions : Shanghai Jiao Tong University, Chinese University of Hong Kong, Lawson Health Research Institute, The University of Texas MD Anderson Cancer Center, Huazhong University of Science and Technology
Ses articles
- Tumor associated depression, gut microbiota, and immune checkpoint inhibitor sensitivity
- Gut microbiome modulates carcinogenesis, immunotherapy efficacy and treatment resistance
- Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response
- Microbiome Signatures in Cancer Immunotherapy
- The microbiome in cancer
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
- The gut microbiota in cancer immunity and immunotherapy
- Gut microbiota shapes cancer immunotherapy responses
- The Interplay Between the Gut Microbiome and Immunotherapy in Gastrointestinal Malignancies: Mechanisms, Clinical Implications, And Therapeutic Potential
- Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials
- Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
- The role of the gut microbiota in tumor, immunity, and immunotherapy
- Microbiome and cancer immunotherapies
- Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
- Microbiome bacterial influencers of host immunity and response to immunotherapy
- Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
- Influence of Microbiota on Tumor Immunotherapy
- The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
- Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
- The Influence of the Microbiome on Immunotherapy for Gastroesophageal Cancer
- Characterization of intratumor microbiome in cancer immunotherapy
- Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
- Implication of gut microbiome in immunotherapy for colorectal cancer
- The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
- Association of the gut microbiome with cancer immunotherapy
- Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
-
Clinical Response and Toxicity Associations
These papers use patient microbiome profiling, cross-cohort comparisons, and evidence synthesis to examine associations of microbial composition, diversity, and function with checkpoint inhibitor response and immune-related adverse events.
Personnes : Karla A. Lee, Rinse Karel Weersma, Haitao Zhao, Johannes R. Björk, Laura A. Bolte, Bertrand Routy
Institutions : University Medical Center Groningen, University of Groningen, The University of Texas MD Anderson Cancer Center, Centre Hospitalier de l’Université de Montréal, Shanghai Jiao Tong University
Ses articles
- Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma
- Gut Microbiome Composition and Response to Immune Checkpoint Inhibitors in Melanoma: A Systematic Review
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
- GUT MICROBIOME DETERMINANTS OF IMMUNE CHECKPOINT INHIBITOR RESPONSE IN CANCER
- Microbiome and response to immunotherapy in malignant melanoma
- The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer
- Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study
- Gut microbiome and immune checkpoint inhibitor toxicity
- 73 Fasting mediated gut microbiome modulation improves response to immune checkpoint therapy in Renal Cell Cancer
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
- Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events
- Gut microbial structural variation associates with immune checkpoint inhibitor response
- Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
- Effects of concomitant gut-microbiome altering medications on immune checkpoint inhibitors therapy: A retrospective study.
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
- De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy: A Pilot Study
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
-
Microbiome Signatures for Response Prediction
These papers investigate predictive microbial signatures, particularly in lung cancer and across cancer cohorts, using clinical profiling, metagenomics, and machine learning to assess taxonomic, functional, and gene-level features.
Personnes : Bertrand Routy, Meriem Messaoudene, Rinse Karel Weersma, Daniel J. Spakowicz, Jie Hong, Khoudia Diop
Institutions : Shanghai Jiao Tong University, University Medical Center Groningen, University of Groningen, Centre Hospitalier de l’Université de Montréal, Renji Hospital
Ses articles
- Gut Microbiome Signatures and Immune Checkpoint Inhibitor Response in Gastrointestinal Cancers: Reproducibility and Translational Readiness
- Microbiome as a prediction of immunotherapy response in lung cancer
- Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP
- Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types
- Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
- Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer
- Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- 1265 Associations of the gut microbiome with immune checkpoint inhibitor response across different cancer types and cohorts identified using random forest and language models
- Exploring gut microbiome markers in predicting efficacy of immunotherapy against lung cancer.
- Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy
- Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
- A gut microbial signature for combination immune checkpoint blockade across cancer types
- Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
- The gut microbiome affects response of treatments in HER2‐negative advanced gastric cancer
- Abstract 650: A machine learning model accurately predicts response to immune checkpoint inhibitors in colorectal cancer using the gut microbiome
- Abstract 3523: A Black Raspberry dietary intervention to modify the gut microbiome and improve the response to immune checkpoint inhibitors
-
Microbiome Modulation and Clinical Links
Based on their titles alone, these papers address microbiome regulation and targeted modulation of checkpoint responses, modeling treatment efficacy, a possible obesity-related mechanism, and associations with recurrence-free survival after adjuvant melanoma treatment.
Personnes : Georgina Venetia Long, Rebecca C. Simpson, Karla A. Lee
Ses articles
- Gut microbiome in modulating immune checkpoint inhibitors
- Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade
- The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
- Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
- Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
- Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer
Articles
- Gut Microbiome Signatures and Immune Checkpoint Inhibitor Response in Gastrointestinal Cancers: Reproducibility and Translational Readiness
- Gut microbiome in modulating immune checkpoint inhibitors
- Gut Microbiome Control of Tumor Immune Checkpoint Inhibitor Response: Mechanistic Insights and Clinical Translation
- Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therapeutic implications-a narrative review
- Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma
- Gut Microbiome Composition and Response to Immune Checkpoint Inhibitors in Melanoma: A Systematic Review
- Microbiome as a prediction of immunotherapy response in lung cancer
- Tumor associated depression, gut microbiota, and immune checkpoint inhibitor sensitivity
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review
- Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP
- Gut microbiome modulates carcinogenesis, immunotherapy efficacy and treatment resistance
- Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer
- Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types
- Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade
- Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives
- Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
- Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer
- Gut Microbiota and Immune Checkpoint Inhibitors: A Synergistic Approach in Hepatocellular Carcinoma Therapy
- GUT MICROBIOME DETERMINANTS OF IMMUNE CHECKPOINT INHIBITOR RESPONSE IN CANCER
- Microbiome and response to immunotherapy in malignant melanoma
- Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response
- Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
- The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists
- The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer
- Microbiome dysbiosis and KRAS-driven tumorigenesis in pancreatic cancer: implications for immune checkpoint inhibitors efficacy
- Microbiome Signatures in Cancer Immunotherapy
- Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
- The microbiome in cancer
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
- Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer
- The gut microbiota in cancer immunity and immunotherapy
- Gut microbiota shapes cancer immunotherapy responses
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
- The Interplay Between the Gut Microbiome and Immunotherapy in Gastrointestinal Malignancies: Mechanisms, Clinical Implications, And Therapeutic Potential
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- Microbiota-centered interventions to boost immune checkpoint blockade therapies
- Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study
- The gut microbiome and cancer response to immune checkpoint inhibitors
- Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
- Gut microbiome and immune checkpoint inhibitor toxicity
- Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
- Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials
- Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors
- Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
- 1265 Associations of the gut microbiome with immune checkpoint inhibitor response across different cancer types and cohorts identified using random forest and language models
- Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer
- Microbial Allies: How Gut Microbiota Influence the Effectiveness of Immune Checkpoint Inhibitors
- The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
- 73 Fasting mediated gut microbiome modulation improves response to immune checkpoint therapy in Renal Cell Cancer
- The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
- Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma
- The role of the gut microbiota in tumor, immunity, and immunotherapy
- Exploring gut microbiome markers in predicting efficacy of immunotherapy against lung cancer.
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
- Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy
- Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
- Microbiome and cancer immunotherapies
- Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
- Microbiome bacterial influencers of host immunity and response to immunotherapy
- Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?
- A gut microbial signature for combination immune checkpoint blockade across cancer types
- Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events
- Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)
- Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
- Influence of Microbiota on Tumor Immunotherapy
- Gut microbial structural variation associates with immune checkpoint inhibitor response
- Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
- The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
- Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
- The Influence of the Microbiome on Immunotherapy for Gastroesophageal Cancer
- Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
- Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
- Characterization of intratumor microbiome in cancer immunotherapy
- The gut microbiome affects response of treatments in HER2‐negative advanced gastric cancer
- Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
- Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota
- Effects of concomitant gut-microbiome altering medications on immune checkpoint inhibitors therapy: A retrospective study.
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
- De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
- Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
- Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy: A Pilot Study
- Abstract 650: A machine learning model accurately predicts response to immune checkpoint inhibitors in colorectal cancer using the gut microbiome
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity
- Microbiome influencers of checkpoint blockade–associated toxicity
- Modulating the gut microbiome to improve immune checkpoint inhibitor response to cancer: current therapies and emerging methods
- Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors
- Abstract C023: A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer
- Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
- Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
- The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application
- Implication of gut microbiome in immunotherapy for colorectal cancer
- Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?
- The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
- Gut microbiome in modulating immune checkpoint inhibitors
- Gut Microbiota and Immunotherapy
- Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer
- Abstract 3523: A Black Raspberry dietary intervention to modify the gut microbiome and improve the response to immune checkpoint inhibitors
- Association of the gut microbiome with cancer immunotherapy
- Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
- Gut Microbiota Potentiates the Effect of Immune Checkpoint Therapy against Cancers
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
- The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
Utiliser cette carte
Exporter : personnes (CSV) · institutions (CSV) · articles (CSV) · BibTeX · RIS (Zotero, Mendeley, EndNote)
D'après les métadonnées des articles dans OpenAlex, qui peuvent être incomplètes (affiliations, homonymes). Vérifiez avant de contacter qui que ce soit.